CW June 2006
Volume 15Issue Number 6 June 2006 ISSN 10593802 Gleevec Continues to Show High Rates of Durable Response for CML After 5 YearsGleevec sets new treatment standard in chronic myeloid leukemia (CML) with high overall survival, increasing response and decreasing progression. Nearly 90% of patients with Philadelphia chromosome-positive CML are alive at 5 years, with a new analysis showing less than 5% mortality due to CML.
Go to Previous Page Go to Next Page Source & Additional Reading B. Druker, presented at the American Society of Clinical Oncology Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
